Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial

High-Dose versus Low-Dose Corticosteroids in COVID-19 Patients: a Systematic Review and Meta-analysis

“…Of all included studies, there were eight observational studies, 16,18À21,23,25,26 one quasi-experimental study, 17 and three RCTs. 22,24,27 The types of corticosteroids used varied across studies; namely, methylprednisolone, dexamethasone, prednisolone, prednisone, and hydrocortisone. Three studies solely used one type of corticosteroids, 16,24,27 eight studies used more than one type of corticosteroids, 17,18,20À23,25,26 and one study did not specify the type of corticosteroid used.…”

Lidocaine reinforces the anti-inflammatory action of dexamethasone on myeloid and epithelial cells activated by inflammatory cytokines or SARS-CoV-2 infection

“…In this line of treatment, the use of dexamethasone or other corticosteroids that ameliorated the systemic inflammatory immune response has been shown to reduce mortality and length of stay (LOS) in ICU [ 13 ] and has been adopted worldwide. Still, the optimal timing and dosing of this treatment has been matter of clinical investigation[ [35] , [36] , [37] ]. In spite of the benefits of using corticosteroids to treat hospitalized COVID-19 patients, high mortality is still observed in ICUs and additional tools to manage these patients are long awaited, consequently, important efforts to improve anti-inflammatory treatments are ongoing [ 38 ].…”

Treatment Outcome with High versus low-to-moderate Dosing of Corticosteroids in Early vis-a-vis Late-onset Hypoxic Cases of COVID-19: A Multicentric Retrospective Cohort Study

“…Manuel Taboad et al ( Taboada et al, 2021 ) in their RCT showed high-dose dexamethasone to reduce clinical worsening in hypoxic COVID-19 patients. Another three-arm RCT by Toroghi N et al ( Toroghi et al, 2022 ) showed higher doses of dexamethasone increased the adverse events and worsened survival in hospitalized patients compared to low-dose dexamethasone. Again, Maskin, Luis Patricio et al .…”